5,578 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Bought by US Bancorp DE

US Bancorp DE acquired a new position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 5,578 shares of the biotechnology company’s stock, valued at approximately $30,000.

Several other institutional investors have also recently added to or reduced their stakes in ALDX. Acadian Asset Management LLC lifted its holdings in shares of Aldeyra Therapeutics by 106.3% in the 1st quarter. Acadian Asset Management LLC now owns 452,449 shares of the biotechnology company’s stock worth $1,478,000 after purchasing an additional 233,169 shares during the last quarter. Diversified Trust Co bought a new stake in Aldeyra Therapeutics in the second quarter valued at $41,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of Aldeyra Therapeutics during the first quarter valued at $585,000. Federated Hermes Inc. bought a new position in shares of Aldeyra Therapeutics during the second quarter worth about $1,758,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Aldeyra Therapeutics by 7.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 3,446 shares during the period. Institutional investors own 59.71% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Friday, August 9th.

Aldeyra Therapeutics Price Performance

ALDX opened at $4.70 on Tuesday. The stock’s 50 day moving average price is $5.45 and its 200 day moving average price is $4.60. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. Aldeyra Therapeutics, Inc has a 12 month low of $2.43 and a 12 month high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.25). On average, analysts anticipate that Aldeyra Therapeutics, Inc will post -0.89 EPS for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.